His Epidermal growth factor receptor study focuses on Erlotinib and Gefitinib. Ross C. Donehower integrates many fields in his works, including Gefitinib and Epidermal growth factor receptor. He regularly links together related areas like Erlotinib in his Internal medicine studies. His Oncology study frequently draws parallels with other fields, such as Progression-free survival. His research is interdisciplinary, bridging the disciplines of Oncology and Progression-free survival. With his scientific publications, his incorporates both Gastroenterology and Urology. He brings together Urology and Gastroenterology to produce work in his papers. With his scientific publications, his incorporates both Cancer and Rash. In his works, Ross C. Donehower conducts interdisciplinary research on Rash and Cancer.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Dung T. Le;Jennifer N. Uram;Hao Wang;Bjarne R. Bartlett.
The New England Journal of Medicine (2015)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le;Dung T. Le;Jennifer N. Durham;Jennifer N. Durham;Kellie N. Smith;Hao Wang.
Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms.
William P. McGuire;Eric K. Rowinsky;Neil B. Rosenshein;Francis C. Grumbine.
Annals of Internal Medicine (1989)
Taxol: A Novel Investigational Antimicrotubule Agent
Eric K. Rowinsky;Lorranie A. Cazenave;Ross C. Donehower.
Journal of the National Cancer Institute (1990)
Hypersensitivity reactions from taxol.
R B Weiss;R C Donehower;P H Wiernik;T Ohnuma.
Journal of Clinical Oncology (1990)
Clinical toxicities encountered with paclitaxel (Taxol)
Rowinsky Ek;Eisenhauer Ea;Chaudhry;Arbuck Sg.
Seminars in Oncology (1993)
The Current Status of Camptothecin Analogues as Antitumor Agents
William J. Slichenmyer;Eric K. Rowinsky;Ross C. Donehower;Scott H. Kaufmann.
Journal of the National Cancer Institute (1993)
Novel Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor–Secreting Tumor Vaccine for Pancreatic Cancer: A Phase I Trial of Safety and Immune Activation
Elizabeth M. Jaffee;Ralph H. Hruban;Barbara Biedrzycki;Daniel Laheru.
Journal of Clinical Oncology (2001)
Phase II Study of Erlotinib (OSI-774) in Patients With Advanced Hepatocellular Cancer
Philip A. Philip;Michelle R. Mahoney;Cristine Allmer;James Thomas.
Journal of Clinical Oncology (2005)
Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer.
Dung T. Le;Eric Lutz;Jennifer N. Uram;Elizabeth A. Sugar.
Journal of Immunotherapy (2013)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: